Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial.
Final results for the year ended 31 December 2023
The Company is pleased to announce its audited results for the year ended 31 December 2023.
Completion of new facility in San Diego
Proteome Sciences is pleased to announce the completion of installation and setup of equipment in its new US laboratory in San Diego, California. and is therefore now fully operational.
Trading update for the year 2023
The Company announces a trading update to its shareholders.
Launch of Commercial Single Cell Proteomics Services
Proteome Sciences plc is pleased to announce the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents.
Investor Presentation
Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on 19th September 2023 at 10:00am BST.
Interim results for the six months ended 30 June 2023
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2023.